18.04.2017 - 11:15 Author:
Mari Kaunisto

Astellas Pharma and FIMM announce a research collaboration

International pharmaceutical company Astellas Pharma Inc. has initiated a scientific collaboration with Institute for Molecular Medicine Finland (FIMM), at the University of Helsinki, to utilize genetic information in the development of new medical treatments.

This collaboration is based on a cooperative research concept initiated by Professor Aarno Palotie from FIMM and Professor Mark Daly from the Broad Institute of MIT and Harvard, where Finland's unique genetic heritage and extensive sample collections open up great opportunities for pharmaceutical research and international research cooperation. The first collaboration of this kind, announced in 2015, includes three international academic research institutes and four pharmaceutical companies (read more).


Development of new, safe drug treatments is a challenging and expensive process. We foresee that genome-wide biology helps to streamline and accelerate this process. This new collaboration agreement with Astellas reflects the value of the Finnish health research environment.

- Professor Aarno Palotie


The research project is done in collaboration with THL Biobank and the Broad Institute of MIT and Harvard.


Last updated: 18.04.2017 - 11:30